When was Zikani Therapeutics founded?

Zikani Therapeutics was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Zikani Therapeutics located?

Zikani Therapeutics is headquartered in Watertown, United States.

How many employees does Zikani Therapeutics have?

As of Jul 01, 2024, the latest employee count at Zikani Therapeutics is 13.

Is Zikani Therapeutics a funded company?

Zikani Therapeutics is a funded company, having raised a total of $61.7M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 10, 2015.

When was the latest funding round of Zikani Therapeutics?

Zikani Therapeutics' latest funding was a $***** Series B round on Apr 01, 2020, with participation from 3 investors. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $640M in funding in 2026 to date.

Where does Zikani Therapeutics rank among its competitors?

Zikani Therapeutics ranks 433rd amongst 1951 active competitors, of which 452 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Life Biosciences, which secured $80M in Apr, 2026.

Who are the top competitors of Zikani Therapeutics?

Zikani Therapeutics' top competitors include Sutro Biopharma, Synthego and Avidity Biosciences. Among them, Life Biosciences secured the most recent funding round in April, 2026.

Zikani Therapeutics - 2026 Company Profile, Funding & Competitors

Company Details

Zikani Therapeutics is developing therapeutics ribosome targeting macrolides. The company has developed a platform to design and develop the therapeutic Ribosome targeting molecules which can be orally delivered for treating diseases.

Website: zikani.com
Email ID: *****@zikani.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Watertown, United States

Stage

Acqui-Hired

Total Funding

$61.7M in 6 rounds

Latest Funding Round

Series B, Apr 01, 2020, $*****

Investors

Gurnet Point Capital & 6 more

Ranked

433^rd among 1951 active competitors

Employee Count

13 as on Jul 01, 2024

Similar Companies

Sutro Biopharma & 2661 more

View Zikani Therapeutics' full profile

Zikani Therapeutics has raised a total funding of $61.7M over 6 rounds. Its first funding round was on Feb 10, 2015. Its latest funding round was a Series B round on Apr 01, 2020 for $*****. 3 investors participated in its latest round. Zikani Therapeutics has 7 institutional investors.

Here is the list of recent funding rounds of Zikani Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2020	9423609	Series B	6286555	6057322	6225938	4517541
Apr 02, 2018	1755693	Series B	7877071	5363092	8414731	Advent Life Sciences
Mar 26, 2018	6770571	Grant (prize money)	2594486	5942326	9552091	CARB-X

Access funding benchmarks and valuations. Sign up today!

View details of Zikani Therapeutics's funding rounds and investors

Zikani Therapeutics' employee count trend

Zikani Therapeutics has 13 employees as of Jul 24. Here is Zikani Therapeutics's employee count trend over the years:

Employee count trend for Zikani Therapeutics

Uncover Zikani Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zikani Therapeutics include Sutro Biopharma, Synthego and Avidity Biosciences. Here is the list of Top 10 competitors of Zikani Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
3rd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 20 others	70/100
4th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
5th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
7th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Invus & 14 others	64/100
8th	Life Biosciences 2017, Boston (United States), Series D	Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases	$261M	Alpha Wave Global, Globalive Capital & 12 others	64/100
9th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 12 others	63/100
10th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
433rd	Zikani Therapeutics 2015, Watertown (United States), Acqui-Hired	Developer of ribosome targeting macrolides	$61.7M	Advent Life Sciences, Roche & 5 others	35/100